Emergent Biosolutions (EBS) 28.76 $EBS
25.0% Return Seen to Date on SmarTrend Emergent Biosolutions Call (EBS)
Comtex SmarTrend(R) - Fri Feb 13, 9:48AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 4 months, Emergent Biosolutions has returned 24.98% as of today's recent price of $28.82.
EBS: 28.76 (-0.12)
Emergent BioSolutions Announces Primary Endpoints Met in Pivotal Study Supporting Licensure of Building 55
GlobeNewswire - Fri Feb 13, 6:00AM CST
Emergent BioSolutions Inc. (NYSE:EBS) today announced completion of the in-life phase of the pivotal nonclinical efficacy study designed to demonstrate that BioThrax(Anthrax Vaccine Adsorbed) manufactured at large scale in the company's new modern facility, Building 55, is comparable to the BioThrax currently manufactured in its approved facility, Building 12. Interim analysis has shown that the primary endpoints were met; these include demonstrating comparability to vaccine manufactured in Building 12 as well as consistency between lots manufactured in Building 55. Data from this study will be used to support a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for licensure of Building 55. BioThrax is the only FDA-licensed vaccine for the prevention of anthrax disease.
EBS: 28.76 (-0.12)
Emergent BioSolutions to Release Fourth Quarter and Full Year 2014 Financial Results and Conduct a Conference Call on March 5, 2015
GlobeNewswire - Thu Feb 12, 6:16AM CST
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, March 5, 2015 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2014, recent business developments, financial outlook for full year 2015, and revenue guidance for the first quarter of 2015.
EBS: 28.76 (-0.12)
Shares of EBS Up 22.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 06, 9:20AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 3 months, Emergent Biosolutions has returned 22.40% as of today's recent price of $28.22.
EBS: 28.76 (-0.12)
Emergent Biosolutions Up 24.1% Since SmarTrend Uptrend Call (EBS)
Comtex SmarTrend(R) - Thu Jan 22, 11:21AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 3 months, Emergent Biosolutions has returned 24.14% as of today's recent price of $28.62.
EBS: 28.76 (-0.12)
Emergent BioSolutions Provides Preliminary 2014 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 5:30PM CST
Emergent BioSolutions (EBS) announced preliminary results for 2014 and provided an outlook for 2015.
EBS: 28.76 (-0.12), ALXN: 182.29 (+6.02), AMGN: 153.48 (+0.30), RGDO: 1.17 (+0.02)
Emergent Bio reports preliminary Q4 results and provides 2015 guidance
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 2:14PM CST
EBS: 28.76 (-0.12)
Emergent BioSolutions Announces Preliminary 2014 Financial Results and Provides 2015 Financial Outlook
GlobeNewswire - Sun Jan 11, 2:00PM CST
-- 2014 Preliminary Estimates:
EBS: 28.76 (-0.12)
Senseonics Announces New CFO
Marketwired - Thu Jan 08, 11:01PM CST
Senseonics, Inc., a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system, today announced the appointment of R. Don Elsey as the company's new Chief Financial Officer.
EBS: 28.76 (-0.12), RGDO: 1.17 (+0.02)
Shares of EBS Up 15.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 08, 9:51AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 2 months, Emergent Biosolutions has returned 15.72% as of today's recent price of $26.68.
EBS: 28.76 (-0.12)
Emergent BioSolutions to Participate in January 2015 Investor Conferences
GlobeNewswire - Wed Jan 07, 6:00AM CST
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in January 2015:
EBS: 28.76 (-0.12), JPM: 59.67 (+0.10)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Uptrend Call Working As Emergent Biosolutions Stock Rises 16.6% (EBS)
Comtex SmarTrend(R) - Fri Dec 19, 9:48AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 2 months, Emergent Biosolutions has returned 16.63% as of today's recent price of $26.89.
EBS: 28.76 (-0.12)
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), EBS: 28.76 (-0.12), SCMP: 15.32 (+0.04)
Evolva disposes EV-035 series programme to Emergent BioSolutions
M2 - Thu Dec 18, 4:59AM CST
Evolva Holding SA (SIX:EVE), a health, wellness and nutrition company, announced on Wednesday the acquisition by Emergent BioSolutions Inc (NYSE:EBS) of Evolva's anti-bacterial programme, the EV-035 series.
EBS: 28.76 (-0.12)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Emergent BioSolutions Expands Biodefense Franchise; Acquires Portfolio of Broad Spectrum Antibiotics
GlobeNewswire - Wed Dec 17, 6:00AM CST
-- Lead antibiotic candidate currently under DTRA development contract, valued at up to $15 million, as an oral and IV treatment for Burkholderia pseudomallei as well as other bioterror agents
EBS: 28.76 (-0.12)
25.0% Return Seen to Date on SmarTrend Emergent Biosolutions Call (EBS)
Comtex SmarTrend(R) - Fri Feb 13, 9:48AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 4 months, Emergent Biosolutions has returned 24.98% as of today's recent price of $28.82.
EBS: 28.76 (-0.12)
Emergent BioSolutions Announces Primary Endpoints Met in Pivotal Study Supporting Licensure of Building 55
GlobeNewswire - Fri Feb 13, 6:00AM CST
Emergent BioSolutions Inc. (NYSE:EBS) today announced completion of the in-life phase of the pivotal nonclinical efficacy study designed to demonstrate that BioThrax(Anthrax Vaccine Adsorbed) manufactured at large scale in the company's new modern facility, Building 55, is comparable to the BioThrax currently manufactured in its approved facility, Building 12. Interim analysis has shown that the primary endpoints were met; these include demonstrating comparability to vaccine manufactured in Building 12 as well as consistency between lots manufactured in Building 55. Data from this study will be used to support a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for licensure of Building 55. BioThrax is the only FDA-licensed vaccine for the prevention of anthrax disease.
EBS: 28.76 (-0.12)
Emergent BioSolutions to Release Fourth Quarter and Full Year 2014 Financial Results and Conduct a Conference Call on March 5, 2015
GlobeNewswire - Thu Feb 12, 6:16AM CST
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, March 5, 2015 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2014, recent business developments, financial outlook for full year 2015, and revenue guidance for the first quarter of 2015.
EBS: 28.76 (-0.12)
Shares of EBS Up 22.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 06, 9:20AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 3 months, Emergent Biosolutions has returned 22.40% as of today's recent price of $28.22.
EBS: 28.76 (-0.12)
Emergent Biosolutions Up 24.1% Since SmarTrend Uptrend Call (EBS)
Comtex SmarTrend(R) - Thu Jan 22, 11:21AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 3 months, Emergent Biosolutions has returned 24.14% as of today's recent price of $28.62.
EBS: 28.76 (-0.12)
Emergent BioSolutions Provides Preliminary 2014 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 5:30PM CST
Emergent BioSolutions (EBS) announced preliminary results for 2014 and provided an outlook for 2015.
EBS: 28.76 (-0.12), ALXN: 182.29 (+6.02), AMGN: 153.48 (+0.30), RGDO: 1.17 (+0.02)
Emergent Bio reports preliminary Q4 results and provides 2015 guidance
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 2:14PM CST
EBS: 28.76 (-0.12)
Emergent BioSolutions Announces Preliminary 2014 Financial Results and Provides 2015 Financial Outlook
GlobeNewswire - Sun Jan 11, 2:00PM CST
-- 2014 Preliminary Estimates:
EBS: 28.76 (-0.12)
Senseonics Announces New CFO
Marketwired - Thu Jan 08, 11:01PM CST
Senseonics, Inc., a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system, today announced the appointment of R. Don Elsey as the company's new Chief Financial Officer.
EBS: 28.76 (-0.12), RGDO: 1.17 (+0.02)
Shares of EBS Up 15.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 08, 9:51AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 2 months, Emergent Biosolutions has returned 15.72% as of today's recent price of $26.68.
EBS: 28.76 (-0.12)
Emergent BioSolutions to Participate in January 2015 Investor Conferences
GlobeNewswire - Wed Jan 07, 6:00AM CST
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in January 2015:
EBS: 28.76 (-0.12), JPM: 59.67 (+0.10)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Uptrend Call Working As Emergent Biosolutions Stock Rises 16.6% (EBS)
Comtex SmarTrend(R) - Fri Dec 19, 9:48AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 2 months, Emergent Biosolutions has returned 16.63% as of today's recent price of $26.89.
EBS: 28.76 (-0.12)
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), EBS: 28.76 (-0.12), SCMP: 15.32 (+0.04)
Evolva disposes EV-035 series programme to Emergent BioSolutions
M2 - Thu Dec 18, 4:59AM CST
Evolva Holding SA (SIX:EVE), a health, wellness and nutrition company, announced on Wednesday the acquisition by Emergent BioSolutions Inc (NYSE:EBS) of Evolva's anti-bacterial programme, the EV-035 series.
EBS: 28.76 (-0.12)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Emergent BioSolutions Expands Biodefense Franchise; Acquires Portfolio of Broad Spectrum Antibiotics
GlobeNewswire - Wed Dec 17, 6:00AM CST
-- Lead antibiotic candidate currently under DTRA development contract, valued at up to $15 million, as an oral and IV treatment for Burkholderia pseudomallei as well as other bioterror agents
EBS: 28.76 (-0.12)
